IP Group's investment in Oxford Nanopore gains in value
IP Group's stake in portfolio company Oxford Nanopore Technologies has gained in value after the DNA sequencing outfit raised £100m from IP, Woodford Investment Management and GT Healthcare.
Financial Services
15,977.07
17:10 24/09/24
FTSE 250
20,770.12
17:09 24/09/24
FTSE 350
4,567.19
17:10 24/09/24
FTSE All-Share
4,523.37
16:39 24/09/24
IP Group
47.15p
16:44 24/09/24
FTSE 250-listed IP's 19.7% stake, including the £19.5m it has invested this year, was valued at £246.3m representing an unrealised fair value gain to the Group of £32.5m.
Oxford Nanopore, which has designed and sells the world's only portable DNA/RNA sequencer, raised the funds to help expand its commercial operations across a range of territories.
The portable MinION DNA sequencing technology, which was based on the science of Professor Hagan Bayley of the University of Oxford, recently completed its own sequencing of a human genome, which analysts said had opened up the human genome to analysis using the platform, increasing its relevance to a greater breadth of scientists at a much more cost-effective level.
The latest found of investment lifts the total funds raised by Oxford Nanopore since its formation in 2005 to £351m.